A Phase 1 interventional study of PA9159 nasal spray solution, 80 μg one day treatment and PA9159 nasal spray solution, 160 μg one day treatment in Allergic Rhinitis, sponsored by Anhui Palo Alto Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Anhui Palo Alto Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Rhinitis, Allergic with a site in China — 32 open to participants now, 34 under way, 2 of them phase 3. Rhinitis, Allergic · China.
Among the 82 studies in Rhinitis, Allergic with a site in China, this one is the 59th largest by enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2025, is one of 8 in phase 1, and was the 73rd registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →32 of the 82 studies in Rhinitis, Allergic with a site in China are open now. Recruiting first, the newest first:
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 5–18
Pengfei Qiu · Sites in China
Ages 18–75
Inmunotek S.L. · Sites in China, Argentina, Portugal and 1 more country
Ages 12–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 11 · Phase 4 9
First in 2006; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 93 across the 67 interventional studies, 270 across the 15 observational. Of the 40 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
Anhui Palo Alto Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Anhui Palo Alto Pharmaceuticals, Inc. has 3 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
8 of the studies in Rhinitis, Allergic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07711262Phase 3Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | 2027-10 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07784491Zhongshan Torch Development Zone People's HospitalSphenopalatine Ganglion Acupuncture for Allergic Rhinitis | 2026-12-31 |
| NCT07079748LanZhou UniversityStudy of the Effects and Mechanisms of Yeast Postbiotics on Persistent Allergic Rhinitis Symptoms | 2026-12-31 |
| NCT07453771The Affiliated Hospital of Qingdao UniversitySafety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 82 studies in Rhinitis, Allergic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy chinese adult
This is a randomized, double-blind, placebo-controlled dose escalation phase 1 trial, including single dose and 7-day repeat doses of PA9159 nasal spray. In the study, the treatment is given once for one day, with escalation doses of 80 μg, 160 μg, 320 μg. After two days elution, PA9159 at the escalation dose of 80 μg, 160 μg, 320 μg is given once a day for 7 days. 12 health subjects will be enrolled for each dose group, randomized proportionally at 3:1 ratio to receive either the investigational product PA9159 or placebo nasal spray, with a total of 36 subjects for this two-part study. Subjects will be evaluated for the safety, tolerability and pharmacokinetics of PA9159 intranasal spray.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either single dose of 80 μg PA9159 or placebo. There will be a follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
Drug: PA9159 nasal spray solution, 80 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient
Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either single dose of 160 μg PA9159 or placebo. There will be a follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
Drug: PA9159 nasal spray solution, 160 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient
Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either single dose of 320 μg PA9159 or placebo. There will be a follow-up period to review all available clinical and laboratory safety data.
Drug: PA9159 nasal spray solution, 320 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient
Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 80 μg PA9159 or placebo once a day for 7 days. There will be follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
Drug: PA9159 nasal spray solution, 80 μg 7-day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient
Twelve Ten subjects will be randomly assigned at a 3: 1 ratio to receive either 160 μg PA9159 or placebo once a day for 7 days. There will be follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
Drug: PA9159 nasal spray solution, 160 μg 7-day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient
Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 320 μg PA9159 or placebo once a day for 7 days. There will be a follow-up period to review all available clinical and laboratory safety data.
Drug: PA9159 nasal spray solution, 320 μg 7-day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient
Single dose of PA9159 (20 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.nostril.
Single dose of PA9159 (40 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Single dose of PA9159 (80 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Repeated doses of PA9159 (20 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Repeated doses of PA9159 (40 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Repeated doses of PA9159 (80 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
Number of subjects experiencing adverse events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment.
Time frame: up to 7 days after last nasal spray treatment
Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-Cmax
Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Maximum Observed Plasma Concentration (Cmax)
Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 0.5, 1, 1, 2, 4, 6, 8, 12,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6
Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-Tmax
Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 0.5, 1, 1, 2, 4, 6, 8, 12,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6
Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-AUC
Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Area Under the Plasma Concentration-Time Curve (AUC)
Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 0.5, 1, 1, 2, 4, 6, 8, 12,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6
Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-T1/2
Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Half-Life Period (T1/2)
Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 0.5, 1, 1, 2, 4, 6, 8, 12,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Jun 2025, 2 months.
Of 25 phase 1 interventional studies under Rhinitis, Allergic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PA9159
Anhui Palo Alto Pharmaceuticals, Inc.